(Reuters) – Bayer AG said on Monday it has signed an agreement with Atara Biotherapeutics Inc to manufacture and sell Atara’s cancer therapy.
Bayer will make an upfront payment of $60 million, it said in a statement.
Atara said in November its CAR T-cell therapy for solid tumors, ATA3271, showed anti-tumor activity in vitro in a pre-clinical study.
(Reporting by Shubham Kalia in Bengaluru; Editing by Arun Koyyur)
